Boston Scientific Corporation

(New York Stock Exchange)
Back to all articles
Somewhat Bearish -25

Boston Scientific stock slips after Citi downgrade and cyberattack fallout

AI-generated analysis

πŸ“‰ Boston Scientific stock closed at $43.55 on September 17, 2026, trading near its 52-week low of $42.20 after a significant decline year-to-date.

πŸ”» Citigroup downgraded the company from Buy to Neutral and lowered its price target from $57 to $50 due to cyberattack fallout and competitive pressures.

πŸ’» An August cyberattack disrupted global operations, temporarily impairing the ability to process orders, though major distribution centers are now operating at normal levels.

πŸ“Š Q2 2026 organic sales grew 7%, meeting the top of the guidance range for that specific quarter despite a reduction in full-year revenue guidance.

πŸ”Ό TD Cowen maintained a Buy rating with a $56 price target, while Stifel kept a Buy rating with a $60 target, citing operational restoration efforts.

πŸ’° GuruFocus models the stock as approximately 59.8% undervalued with a fair value estimate of $107.27 versus the current trading price.

Bullish Signals
  • Boston Scientific reported Q2 2026 organic sales growth of 7%, which hit the top end of the company's guidance range for that period.
  • Major distribution centers have returned to operating at or above normal levels following the August cyberattack disruption.
  • TD Cowen maintains a Buy rating with a $56 price target, indicating confidence in the company's longer-term prospects despite short-term setbacks.
  • Stifel reiterated a Buy rating with a $60 price target, acknowledging operational disruptions but emphasizing the company's progress in restoring its business.
Risk Factors
  • Citigroup downgraded Boston Scientific from Buy to Neutral and lowered its price target from $57 to $50 due to ongoing operational challenges.
  • The August cyberattack has caused lingering operational disruptions, affecting information systems and temporarily impairing the ability to process customer orders.
  • Intensifying competition in key medical device markets is cited as a factor contributing to the company's current operational challenges and stock weakness.
Full Analysis
Boston Scientific stock closed at $43.55 on September 17, 2026, near its 52-week low following a downgrade by Citigroup and the lingering effects of an August cyberattack. The medical device manufacturer faces intensified competition in key markets while navigating operational disruptions that have temporarily impaired its ability to process and ship customer orders globally. Citigroup cut its rating from Buy to Neutral and lowered its price target from $57 to $50, citing ongoing challenges related to the cyber incident and slower growth in core segments. Despite these headwinds, Q2 2026 organic sales grew 7%, hitting the top of the company's guidance range for that period, though full-year 2026 revenue guidance was reduced to a 5% to 6% growth range in late July. Analyst sentiment remains mixed as other firms maintain bullish stances. TD Cowen reiterated a Buy rating with a $56 price target, while Stifel maintained a Buy with a $60 target, acknowledging disruptions but highlighting the company's efforts to restore operations and its longer-term prospects.